Addition of fucose to a cell-surface glycoprotein receptor demonstrates the power of glycan engineering to direct homing of adult stem cells to a tissue of choice. Stem cells hold great promise ...
The question of how life began has intrigued people for many years. While we may never know the answer, several research avenues exist – each with their own theories and starting conditions.
Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design.
MCLA-145 is under clinical development by Merus and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData, Phase I drugs for Merkel Cell Carcinoma have an 82% phase transition ...
PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated ...
Petosemtamab, or MCLA-158, is a bispecific Biclonics® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing ...
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentationUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024(Nasdaq: MRUS) (Merus, the Company, we, or our), a clin ...